This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke for an investor and industry update in the personalised medicine and cancer therapy space. 

During the interesting 30 minute session, he discussed the evolution of cancer treatments, what personalised medicines could mean for patients, and PTX’s astounding progress in clinical studies, new CAR-T cell therapy collaborations and future proofing the company.

Avoiding overly complicated jargon, Steven addresses the industry landscape and clinical trials in easy to understand terms, and explains why CAR-T and targeted therapies are hot topics amongst professionals in oncology business development and the biotech industry.

Watch the full Investor Briefing below, including the Q&A session where Steven responds to questions such as, when he expects the personalised cancer medicines to be market ready, and what sets PTX apart from other clinical trial companies.

Reach Markets have been engaged by PTX to assist with private investor management.

Presented on Tuesday the 26th of November at 12pm (AEDT).